Letter | Published:

Phytohaemagglutinin activation of T cells through the sheep red blood cell receptor

Naturevolume 313pages686687 (1985) | Download Citation

Subjects

Abstract

Expression of receptors for sheep red blood cells and the ability to proliferate in response to phytohaemagglutinin (PHA) are the traditional properties of human T cells1,2, but the function of the sheep red cell receptor (the T11 antigen) is controversial3,4 and the mechanism of PHA-induced mitogenesis unclear. Mitogenesis involves a complex series of cell-mediated and factor-dependent interactions, but a rise in intracellular free calcium concentration, [Ca2+]i, seems to be an important primary event in T-cell activation5–7. We have now investigated the effects of three monoclonal antibodies, previously shown to inhibit mitogen-induced proliferation3,8,9, on T-cell [Ca2+]i. We find that anti-LFA-2 and OKT11, which react with the sheep red cell receptor8,10, have no effect on [Ca2+]i, nor do they inhibit the rise in [Ca2+]i induced by concanavalin A (Con A) or the mitogenic anti-T3 monoclonal antibody UCHT1 (ref. 11). They do, however, block PHA-induced Ca2+ mobilization. Anti-LFA-1, which reacts with the lymphocyte function-associated antigen8,12, has no effect on intracellular Ca2+. These studies suggest that the sheep red blood cell receptor is an activation pathway for T cells and that the effects of PHA are mediated through this pathway.

References

  1. 1

    Greaves, M. F. & Janossy, G. Transplantn Rev. 11, 87–130 (1973).

  2. 2

    Coombs, R. R. A., Gumer, B. W., Wilson, A. B., Holm, G. & Lindgren, B. Int. Archs Allergy appl. Immun. 39, 658–663 (1970).

  3. 3

    Palacios, R. & Martinez-Maza, O. J. Immun. 129, 2479–2485 (1982).

  4. 4

    Meuer, S. C. et al. Cell 36, 897–906 (1984).

  5. 5

    Lichtman, A. H., Segal, G. B. & Lichtman, M. A. Blood 61, 413–422 (1983).

  6. 6

    Metcalfe, J.C., Pozzan, T., Smith, G.A. & Hesketh, T.R. Biochem. Soc. Symp. 45, 1–26 (1980).

  7. 7

    Tsien, R. Y., Pozzan, T. & Rink, T. J. Nature 295, 68–71 (1982).

  8. 8

    Krensky, A. M. et al. J. Immun. 131, 611–616 (1983).

  9. 9

    Martin, P. J. J. Immun. 131, 180–185 (1983).

  10. 10

    Verbi, W. et al. Eur. J. Immun. 12, 81–86 (1981).

  11. 11

    Beverley, P. C. L. & Callard, R. E. Eur. J. Immun. 11, 329–344 (1981).

  12. 12

    Sanchez-Madrid, F. et al. Proc. natn. Acad. Sci. U.S.A. 79, 7489–7493 (1982).

  13. 13

    O'Flynn, K., Linch, D. C. & Tatham, P. E. R. Biochem. J. 219, 661–666 (1984).

  14. 14

    O'Flynn, K. et al. Eur. J. Immun. (in the press).

  15. 15

    Beverley, P. C. L. Nature 304, 398–399 (1983).

  16. 16

    Beverley, P. C. L. Proc. R. Soc. Edinb. B81, 221–232 (1982).

  17. 17

    Beverley, P. C. L., Linch, D. C. & Delia, D. Nature 287, 332 (1980).

  18. 18

    Gazdar, A. F. et al. Blood 55, 409–417 (1980).

  19. 19

    Minowada, J., Sagawa, K., Trowbridge, I. S., Kung, P. D. & Goldstein, G. in Malignant Melanomas (eds Rosenberg, S. A. & Kaplan, H. S.) 53–74 (Academic, New York, 1982).

Download references

Author information

Affiliations

  1. Department of Haematology, University College Medical School, 98 Chenies Mews, London, WC1E 6HX, UK

    • Kieran O'Flynn
    •  & David C. Linch
  2. Department of Paediatric Oncology, Dana-Farber Cancer Institute, 44 Binney Street, Boston, Massachusetts, 02115, USA

    • Alan M. Krensky
    •  & Steven J. Burakoff
  3. Imperial Cancer Research Fund, Human Tumour Immunology Group, University College Medical School, University Street, London, WC1, UK

    • Peter C. L. Beverley

Authors

  1. Search for Kieran O'Flynn in:

  2. Search for Alan M. Krensky in:

  3. Search for Peter C. L. Beverley in:

  4. Search for Steven J. Burakoff in:

  5. Search for David C. Linch in:

About this article

Publication history

Received

Accepted

Issue Date

DOI

https://doi.org/10.1038/313686a0

Further reading

Comments

By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.